Torrent Pharma Q3 FY 2025‑26: Strong Earnings, Dividend Boost and Growth Plans
Torrent Pharmaceuticals’ Q3 FY 2025‑26 update shows strong revenue growth, an approved interim dividend and plans to scale production, reinforcing its value‑focused strategy for shareholders.
- Torrent Pharmaceuticals Limited
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read